Now Approved
VABYSMO's Journey:
Global Reach and Updated Drying Data
VABYSMO has reached more than 100 countries with a total of over 8 million doses distributed in just 3 years.1,2
Drying Data
VABYSMO®▼ has reached more than 100 countries with a total of over 8 million doses distributed in just 3 years.1,2
Celebrate this milestone in style and with music!
Celebrate this milestone in style and with music!
Fast Drying
Time to first absence of DME* (post hoc analysis)3
VABYSMO achieved absence of DME* faster and with fewer injections compared to aflibercept3
VABYSMO achieved absence of DME* faster and with fewer injections compared to aflibercept3
Sustained Drying
Proportion of patients with absence of DME* at the end of Year 2 and Year 4 (post hoc analysis)3
~95% of patients achieved absence of DME at the end of Year 4 once all patients received VABYSMO3
~95% of patients achieved absence of DME at the end of Year 4 once all patients received VABYSMO3
~95% of patients achieved absence of DME at the end of Year 4 once all patients received VABYSMO3
~95% of patients achieved absence of DME at the end of Year 4 once all patients received VABYSMO3
Strong Drying
Adjusted mean CST change† from baseline (secondary endpoint)4
VABYSMO showed greater† CST reductions compared to aflibercept in the matched dose phase4,5
VABYSMO showed greater† CST reductions compared to aflibercept in the matched dose phase4,6
Hear From the Experts
Dr. Salvatore Di Lauro,
Hospital Clínico Universitario de Valladolid, Spain
“The results are so good that patients themselves ask for it.”
Dr Harit Bhatt,
University Retina, US
“VABYSMO’s ability to rapidly dry the retina is truly impressive. I’ve witnessed its impact on patients with nAMD, DME and RVO‡ in my own clinic, making it my preferred treatment option.”
Prof. Laurent Kodjikian,
University of Lyon, France
“What impresses me most with VABYSMO is both how fast-acting and effective it is. In nearly all my patients with nAMD, DME and RVO‡, whether treatment-naive or refractory, we see a rapid fluid reduction and strong visual outcomes.”
Prof. Dr Arne Viestenz,
University of Halle, Germany
“I love VABYSMO because it works quickly and allows my patients to receive long treatment intervals. This increases their satisfaction and quality of life.”
Dr. Shaheer Aboobaker,
Toronto Retina Institute, Canada
“Dual-inhibition with VABYSMO is proving itself to be a strong contender as a first-line agent in nAMD, DME and RVO‡.”
VABYSMO dosed up to Q16W met the primary endpoint, demonstrating non-inferior vision gains vs. aflibercept 2.0 mg Q8W, averaged over Week 48, 52 and 56 in both YOSEMITE
and RHINE.6
VABYSMO was studied head-to-head vs. aflibercept 2.0 mg over 2 years, followed by RHONE-X, an OLE study through Year 4. In YOSEMITE and RHINE, patients were randomised to either VABYSMO Q8W, VABYSMO up to Q16W or aflibercept 2.0 mg Q8W dosing (n=1891). In RHONE-X (OLE), all patients received VABYSMO up to Q16W (n=1474). The VABYSMO up to Q16W regimen started at Week 100 for VABYSMO Q8W and aflibercept Q8W but not all patients received VABYSMO at Week 100.3,4
* Absence of DME is defined as CST <325 µm.
† Based on post hoc analysis with nominal P-value statistical analysis not adjusted for multiple testing (nominal P-value <0.05 vs. aflibercept 2.0 mg Q8W), no formal statistical conclusions can be drawn.
‡ Macular edema secondary to RVO.
CST, central subfield thickness; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; OLE, open-label extension; Q8W, every 8 weeks; Q16W, every 16 weeks; RVO, retinal vein occlusion; SmPC, summary of product characteristics; US, United States.
References:
- Hatz K, et al. SOG-Jahreskongress 2025.
- Vabysmo (faricimab) SmPC. Roche Registration GmbH; 2022.
- Sheth V, et al. Presented at ASRS 2025.
- Wong TY, et al. Ophthalmol. 2024;131(6):708–23.
- Wykoff CC, et al. Lancet. 2022;399:741–55.
- Lim JI, et al. Ophthalmol. Retina. 2025;9:655–66.
